Dendritic cell-based vaccines: Barriers and opportunities

Jessica A. Cintolo, Jashodeep Datta, Sarah J. Mathew, Brian J. Czerniecki

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


Dendritic cells (DCs) have several characteristics that make them an ideal vehicle for tumor vaccines, and with the first US FDA-approved DC-based vaccine in use for the treatment of prostate cancer, this technology has become a promising new therapeutic option. However, DC-based vaccines face several barriers that have limited their effectiveness in clinical trials. A major barrier includes the activation state of the DC. Both DC lineage and maturation signals must be selected to optimize the antitumor response and overcome immunosuppressive effects of the tumor microenvironment. Another barrier to successful vaccination is the selection of target antigens that will activate both CD8+ and CD4+ T cells in a potent, immune-specific manner. Finally, tumor progression and immune dysfunction limit vaccine efficacy in advanced stages, which may make DC-based vaccines more efficacious in treating early-stage disease. This review underscores the scientific basis and advances in the development of DC-based vaccines, focuses on current barriers to success and highlights new research opportunities to address these obstacles.

Original languageEnglish (US)
Pages (from-to)1273-1299
Number of pages27
JournalFuture Oncology
Issue number10
StatePublished - Oct 2012
Externally publishedYes


  • cancer vaccines
  • dendritic cells
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Dendritic cell-based vaccines: Barriers and opportunities'. Together they form a unique fingerprint.

Cite this